Management of dyslipidemia in primary care

Canadian Journal of Cardiology

Volumn 19, Issue 13, 2003, Pages 1499-1502

  Alzahrani, Turky ^a   Marrat, Saida ^a   Haider, Aamir ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Coronary disease; Diabetes; Dyslipidemia; Statins

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GENERAL PRACTICE; HEALTH CENTER; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE;

AGED; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERLIPIDEMIAS; MALE; PRACTICE GUIDELINES;

EID: 0942266400     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Fodor GJ, Frohlich JJ, Genest JJG, Mcpherson PR. Recommendations for the management and treatment of dyslipidemia. CMAJ 2000;162:1441-7.
2. Fenske TK. Lipid lowering update. Aggressive new goals. Can Fam Physician 2001;47:303-9.
3. Moss SE, Klein R, Klein BEK. Cause specific mortality in a population based study of diabetes. Am J Public Health 1991;81:1158-62.
4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
6. The Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
7. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP). A multicentre survey to evaluate the percentage of dyslipidemic patients receiving lipid lowering therapy and achieving LDL cholesterol levels. Arch Intern Med 2000;160:459-67.
8. Xhignesse M, Laplante P, Grant AM, et al. Antiplatelet and lipid lowering therapies for the secondary prevention of cardiovascular disease: Are we doing enough? Can J Cardiol 1999;15:185-9.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of high blood cholesterol in adults. (Adult Treatment Panel III) JAMA 2001;285:2486-97.
10. No authors listed. Management of dyslipidemia in adults with diabetes. Position statement of the American Diabetes Association. Diabetes Care 2001;24(Suppl 1):S58-61.
11. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
12. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS 23). BMJ 1998;316:823-8.
13. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience. Eur Heart J 1999;20:725-41.
14. Timmis AD. Diabetes. Br Med Bull 2001;59:159-72.
15. Curnew G. The Heart Protection Study. Perspectives in Cardiology 2002:1-5.